GlaxoSmithKline struck two deals to broaden its pipeline: a licensing agreement with Frontier Biotechnologies for two siRNA immunology assets (up to $1 billion in milestones) and a $950 million cash acquisition of 35Pharma to obtain HS‑235, a phase II‑ready candidate for pulmonary hypertension. GSK framed both moves as strategic adds to its immunology and cardiopulmonary portfolios. The transactions signal Big Pharma’s continued appetite to buy or in‑license platform therapeutics and mid‑stage assets to fill near‑term development funnels. For Frontier and 35Pharma, the deals provide capital and global development infrastructure; for GSK, they accelerate entry into oligonucleotide modalities and PAH, areas with high unmet clinical need and clear commercial pathways.